AdipoGen Life Sciences

Colistin sulfate (USP Grade)

CHF 35.00
In stock
AG-CN2-0065-M100100 mgCHF 35.00
AG-CN2-0065-G0011 gCHF 100.00
AG-CN2-0065-G0055 gCHF 350.00
More Information
Product Details
Synonyms Polymyxin E; Belcomycin; Colimycin
Product Type Chemical
Properties
Formula

2(C52H98N16O13) . 5(H2SO4) (unspec.)

MW 2801.7
CAS 1264-72-8
RTECS TR1500000
Source/Host Chemicals Isolated from Bacillus polymyxa.
Purity Chemicals Mixture (primarly colistin A and B).
Appearance White to off-white powder.
Solubility Soluble in water (50mg/ml).
Biological Activity

Potency ≥ 500μg/mg

InChi Key YKQOSKADJPQZHB-QNPLFGSASA-N
Smiles CCC(C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O)[C@@H](C)O
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage +4°C
Handling Advice Keep cool and dry.
Use/Stability Stable for at least 2 years after receipt when stored at +4°C.
Documents
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
Description
  • Very potent polymyxin antibiotic.
  • Has only one amino acid difference compared to polymyxin B.
  • Antimicrobial.
  • Targets the lipopolysaccharide (LPS) of the outer membrane of Gram-negative bacteria. Competitively displaces divalent cations (Ca2+ and Mg2+) from the negatively-charged phosphate groups LPS, causing disruption of the membrane. This increases the permeability of the cell envelope, leakage of cell contents, leading to apoptosis and cell death.
  • Used against multidrug-resistant Gram-negative bacterial infections.
Product References
  1. Antimicrobial drugs, microorganisms, and phagocytes: P.J. van den Broek; Rev. Infect. Dis. 11, 213 (1989) (Review)
  2. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria: M.E. Evans, et al.; Ann. Pharmacother. 33, 960 (1999) (Review)
  3. The clinical use of colistin in patients with cystic fibrosis: P. Beringer; Curr. Opin. Pulm. Med. 7, 434 (2001) (Review)
  4. Update on antimicrobial agents: new indications of older agents: T.R. Pasquale & J.S. Tan; Expert Opin. Pharmacother. 6, 1681 (2005) (Review)
  5. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections: J. Li, et al.; Lancet Infect. Dis. 6, 589 (2006) (Review)
  6. Polymyxin B: similarities to and differences from colistin (polymyxin E): A. Kwa, et al.; Expert Rev. Anti. Infect. Ther. 5, 811 (2007) (Review)
  7. Colistin in the 21st century: R.L. Nation & J. Li; Curr. Opin. Infect. Dis. 22, 535 (2009) (Review)
  8. New information about the polymyxin/colistin class of antibiotics: J. Molina, et al.; Expert Opin. Pharmacother. 10, 2811 (2009) (Review)
  9. Colistin: new lessons on an old antibiotic: D. Yahav, et al.; Clin. Microbiol. Infect. 18, 18 (2012) (Review)
  10. Time-kill and post-antibiotic effect of colistin at different static concentrations in in vitro Acinetobacter baumannii: R.S.M. Rasidin, et al.; Tropical Biomedicine 37, 471 (2020)
  11. A pulmonary mucus surrogate for investigating antibiotic permeation and activity against Pseudomonas aeruginosa biofilms: S. Frisch, et al.; J. Antimicrob. Chemother. 76, 1472 (2021)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.